A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance

European Journal of Clinical Pharmacology

Volumn 64, Issue 7, 2008, Pages 739-741

  Basso, Michele ^a   Cassano, Alessandra ^a   Modoni, Anna ^a   Spada, Daniele ^a   Trigila, Nunziatina ^a   Quirino, Michela ^a   Schinzari, Giovanni ^a   Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUCONATE CALCIUM; OXALIPLATIN; POTASSIUM CHLORIDE;

ADULT; CASE REPORT; COLORECTAL CANCER; COMA; CONTINUOUS INFUSION; DIARRHEA; DIPLOPIA; DYSARTHRIA; ELECTROLYTE DISTURBANCE; FEMALE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; LETHARGY; LETTER; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; PARESTHESIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; UNCONSCIOUSNESS;

ANTINEOPLASTIC AGENTS; COMA; ELECTROLYTES; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 44449168462     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0474-x     Document Type: Letter

References (11)

1. Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895-924
2. de Gramont A, Figer A, Seymour H, Homerin H, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan R, Williamson SK et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
4. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and preventive measures. Semin Oncol 29:21-33
5. Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30[Suppl 4]:5-13
6. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter HK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexitability. J Clin Oncol 20:1767-1774
7. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O et al. (1997) Autoantibodies detected to expressed K channels are implicated in neuromyotonia. Ann Neurol 41:238-246
8. Nagado T, Arimura K, Sonoda Y et al (1999) Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122:2057-2066
9. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A (2005) Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146:1027-1039
10. + channels, hSK3. Cell Physiol Biochem 18:165-176
11. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate H, Gamelin E (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated channels. J Neurophysiol 85:2293-2297